Geron 8-K 2009
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
8.01. Other Events
On January 23, 2009, Geron Corporation (the “Company”) publicly disseminated a press release announcing that the U.S. Food and Drug Administration (FDA) has granted clearance of the Company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
The foregoing description is qualified in its entirety by reference to the Company’s Press Release dated January 23, 2009, a copy of which is attached hereto as Exhibit 99.1.
9.01. Financial Statements and Exhibits
99.1 Press release dated January 23, 2009.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.